3255. A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
Chang Gon Kim1, Min Hee Hong1, Dahee Kim2, Brian Hyohyoung Lee3,4, Hyunwook Kim1,
Chan-Young Ock5, Geoffrey Kelly3, Yoon Ji Bang4, Gamin Kim1, Jung Eun Lee1, Chaeyeon Kim1,
Se-Heon Kim2, Hyun Jun Hong2, Young Min Park2, Nam Suk Sim2, Heejung Park6, Jin Woo Park6,
Chang Geol Lee7, Kyung Hwan Kim7, Goeun Park8, Inkyung Jung8, Dawoon Han9, Jong Hoon Kim9,
Junha Cha10, Insuk Lee10, Mingu Kang5, Heon Song5, Chiyoon Oum5, Seulki Kim5, Sukjun Kim5,
Yoojoo Lim5, Seunghee Kim-Schulze3,11, Miriam Merad3,1
Clin Cancer Res. 2024 May 15;30(10):2097-2110
Link